Is the murine dextran sodium sulfate-induced colitis model valid for predicting drug efficacy in IBD?
|
|
- Holly Jenkins
- 7 years ago
- Views:
Transcription
1 Is the murine dextran sodium sulfate-induced colitis model valid for predicting drug efficacy in IBD? Yvette M Petersen, B. Björkenberg, K. Christjansen, M. Stahlhut, H.D Pedersen and C. Thorkildsen Zealand Pharma A/S Glostrup, Denmark Slide 1 31st May 29 Session Title: Preclinical Treatment of Experimental Intestinal Inflammation
2 Introduction Their is no single animal model of intestinal inflammation that mimics the pathogenesis, pathology, and therapeutic response of IBD Dextran sodium sulfate ()-induced colitis model Spontaneous colitis model Primarily used to assess the therapeutic potential of novel therapies in IBD Most widely used experimental model of ulcerative colitis. Slide 2 31st May 29 Session Title: Preclinical Treatment of Experimental Intestinal Inflammation
3 -induced model of colitis Induction Species Mechanism Features Advantages Disadvantages (2-1% w/v), administered in drinking water for days (5-14 days) followed, in some cases, by a period of normal drinking water Primarily mice but also rats Directly damages epithelial cells leading to the activation of the mucosal immune system Body weight loss, colon shortening, bloody diarrhea, histological damage, neutrophil infiltrations, changes in local cytokine concentrations Reproducible, easy administration, cheap Different pathogenesis vs. IBD Inflammation restricted to the colon Slide 3 31st May 29 Session Title: Preclinical Treatment of Experimental Intestinal Inflammation
4 Rationale Aminosalicylates and corticosteroids, are used to therapeutically suppress inflammation in IBD. There are, however, no systematic reports documenting beneficial dose dependent effects of aminosalicylates and corticosteroids in the model. CRO s offering the model rarely use aminosalicylates and corticosteroids as reference compounds. Slide 4 31st May 29 Session Title: Preclinical Treatment of Experimental Intestinal Inflammation
5 Aim To evaluate the effects of sulfasalazine (aminosalicylate) and dexamethasone (corticosteroid) in CD-1 mice with induced colitis. Slide 5 31st May 29 Session Title: Preclinical Treatment of Experimental Intestinal Inflammation
6 Experimental design Study 1: Sacrifice Study 2: Sacrifice 5% in drinking water Sulfasalazine (Sigma-Aldrich) (5, 1 and 15 mg/kg/d, p.o., once daily) controls (p.o., once daily) 5% in drinking water Dexamethasone (Boehringer Ingelheim ) (.4,.8 and 1.2 mg/kg/d, i.p., once daily) controls (i.p., once daily) Untreated controls were also included in the study Endpoints: Bodyweight, rectal bleeding, stool consistency, colon mass to length ratio, and colon tissue levels of C-reactive protein (CRP), myeloperoxidase (MPO) and proinflammatory cytokines Slide 6 31st May 29 Session Title: Preclinical Treatment of Experimental Intestinal Inflammation
7 Bodyweight in CD-1 mice with -induced colitis Change in bodyweight mg/kg/d Sulfasalazine 1 mg/kg/d Sulfasalazine 15 mg/kg/d Sulfasalazine Change in bodyweight mg/kg/d Dexamethasone.8mg/kg/d Dexamethasone 1.2 mg/kg/d Dexamethasone Sulfasalazine had no effect on bodyweight loss Dexamethasone aggravated bodyweight loss Slide 7 31st May 29 Session Title: Preclinical Treatment of Experimental Intestinal Inflammation
8 Stool consistency in CD-1 mice with -induced colitis Stool Consistency Normal stools Mild diarrhea mg/kg/d Sulfasalazine 1 mg/kg/d Sulfasalazine 15 mg/kg/d Sulfasalazine 3.4mg/kg/d Dexamethasone.8mg/kg/d Dexamethasone 1.2 mg/kg/d Dexamethasone Moderate diarrhea Severe diarrhea 2 3 Stool consistency 2 1 Stool consistency 2 1 Median score Sulfasalazine had no effect on diarrhea severity Dexamethasone had no effect on diarrhea severity Slide 8 31st May 29 Session Title: Preclinical Treatment of Experimental Intestinal Inflammation
9 Colon mass to length in CD-1 mice with -induced colitis 5 5 mg/kg/d Sulfasalazine 1 mg/kg/d Sulfasalazine 15 mg/kg/d Sulfasalazine 5.4mg/kg/d Dexamethasone.8mg/kg/d Dexamethasone 1.2 mg/kg/d Dexamethasone Colon mass/length Colon mass/length Sulfasalazine had no effect on colon mass to length Dexamethasone had no effect on colon mass to length Slide 9 31st May 29 Session Title: Preclinical Treatment of Experimental Intestinal Inflammation
10 Colonic CRP concentrations in CD-1 mice with -induced colitis CRP (U/g protein) mg/kg/d Sulfasalazine 1 mg/kg/d Sulfasalazine 15 mg/kg/d Sulfasalazine CRP (U/ g protein) mg/kg/d Dexamethasone.8mg/kg/d Dexamethasone 1.2 mg/kg/d Dexamethasone Sulfasalazine had no effect on colonic CRP concentrations Dexamethasone had no effect on colonic CRP concentrations Slide 1 31st May 29 Session Title: Preclinical Treatment of Experimental Intestinal Inflammation
11 Colonic MPO concentrations in CD-1 mice with -induced colitis 2 5 mg/kg/d Sulfasalazine 1 mg/kg/d Sulfasalazine 15 mg/kg/d Sulfasalazine 175.4mg/kg/d Dexamethasone.8mg/kg/d Dexamethasone 1.2 mg/kg/d Dexamethasone MPO (U/g protein) MPO (U/ gprotein) Sulfasalazine had no effect on colonic MPO concentrations Dexamethasone had no effect on colonic MPO concentrations Slide 11 31st May 29 Session Title: Preclinical Treatment of Experimental Intestinal Inflammation
12 Colonic TNF-α concentrations in CD-1 mice with -induced colitis TNF-α (U/ g protein) mg/kg/d Sulfasalazine 1 mg/kg/d Sulfasalazine 15 mg/kg/d Sulfasalazine TNF-α (U/g protein) mg/kg/d Dexamethasone.8mg/kg/d Dexamethasone 1.2 mg/kg/d Dexamethasone Sulfasalazine increased colonic TNF-α concentrations Dexamethasone increased colonic TNF-α concentrations Slide 12 31st May 29 Session Title: Preclinical Treatment of Experimental Intestinal Inflammation
13 Colonic IL-1β concentrations in CD-1 mice with -induced colitis 1. 5 mg/kg/d Sulfasalazine 1 mg/kg/d Sulfasalazine 15 mg/kg/d Sulfasalazine 1..4mg/kg/d Dexamethasone.8mg/kg/d Dexamethasone 1.2 mg/kg/d Dexamethasone IL-1β (ug/ml protein) IL-1β (ug/ml protein) Sulfasalazine had no effect on colonic IL-1β concentrations Dexamethasone decreased colonic IL-1β concentrations Slide 13 31st May 29 Session Title: Preclinical Treatment of Experimental Intestinal Inflammation
14 Colonic IL-6 concentrations are increased in CD-1 rats with -induced colitis 2 5 mg/kg/d Sulfasalazine 1 mg/kg/d Sulfasalazine 15 mg/kg/d Sulfasalazine 2.4mg/kg/d Dexamethasone.8mg/kg/d Dexamethasone 1.2 mg/kg/d Dexamethasone IL-6 (U/g protein) IL-6 (U/ gprotein) Sulfasalazine had no effect on colonic IL-6 concentrations Dexamethasone increased colonic IL-6 concentrations Slide 14 31st May 29 Session Title: Preclinical Treatment of Experimental Intestinal Inflammation
15 Discussion Might better effects been attained : Using another mouse strain or another species? With other dosing regimens? Had other types of ASA or corticosteoroids used? Using another regimen? Slide 15 31st May 29 Session Title: Preclinical Treatment of Experimental Intestinal Inflammation
16 Conclusions -induced colitis in CD-1 mice Sulfasalazine treatment had no effect on the majority of colitis endpoints Dexamethasone treatment either had no effect or aggravated the endpoints assessed Slide 16 31st May 29 Session Title: Preclinical Treatment of Experimental Intestinal Inflammation
17 Missing link: From the Laboratory to Clinical Practice Gastro-intestinal peptides Probiotics Plant-derived substances Proven efficacy in the -induced colitis model Anti-TNF agents Corticosteroids Immunomodulators What is the Predictive Value of the Model? Who is convinced by the results? Aminosalicylates Suboptimal / No efficacy demonstrated in the -induced colitis model Not validated clinically Validated clinically Slide 17 31st May 29 Session Title: Preclinical Treatment of Experimental Intestinal Inflammation
In vitro co-culture model of the inflamed intestinal mucosa
In vitro co-culture model of the inflamed intestinal mucosa Berlin, December 13, 2011 Eva-Maria Collnot, e.collnot@mx.uni-saarland.de Helmholtz Institute for Pharmaceutical Research Saarland Departement
More informationProbiotics for the Treatment of Adult Gastrointestinal Disorders
Probiotics for the Treatment of Adult Gastrointestinal Disorders Darren M. Brenner, M.D. Division of Gastroenterology Northwestern University, Feinberg School of Medicine Chicago, Illinois What are Probiotics?
More informationEVIDENCE BASED TREATMENT OF CROHN S DISEASE. Dr E Ndabaneze
EVIDENCE BASED TREATMENT OF CROHN S DISEASE Dr E Ndabaneze PLAN 1. Case presentation 2. Topic on Evidence based Treatment of Crohn s disease - Introduction pathology aetiology - Treatment - concept of
More informationDietary emulsifiers impact the mouse gut microbiota promoting colitis and metabolic syndrome
Dietary emulsifiers impact the mouse gut microbiota promoting colitis and metabolic syndrome Andrew T. Gewirtz et al N A T U R E VOL 519 5 M A R C H 2 0 1 5 Background Incidence of IBD Fact 1: increasing
More informationTHE EFFECTS OF TREADMILL AND VOLUNTARY WHEEL TRAINING ON MORBIDITY AND INFLAMMATION DURING ULCERATIVE COLITIS IN MICE MARC D.
THE EFFECTS OF TREADMILL AND VOLUNTARY WHEEL TRAINING ON MORBIDITY AND INFLAMMATION DURING ULCERATIVE COLITIS IN MICE BY MARC D. COOK DISSERTATION Submitted in partial fulfillment of the requirements for
More informationBriefing Document. Food and Drug Administration. Center for Drug Evaluation and Research
Briefing Document Food and Drug Administration Center for Drug Evaluation and Research Meeting: Joint Meeting of the Gastrointestinal Drugs Advisory Committee (GIDAC) and the Drug Safety and Risk Management
More informationResearch in IBD at University of Colorado Denver
Research in IBD at University of Colorado Denver Blair Fennimore, MD Assistant Professor of Medicine Division of Gastroenterology and Hepatology UCH Crohn s and Colitis Center Mucosal Inflammation Program
More informationA Case for Cure: Drug Portfolio Analysis. Team: PharmaKings Anirvan Chaudhuri Neha Madan Xiao Huang Jason Park Anjai Lal
A Case for Cure: Drug Portfolio Analysis Team: PharmaKings Anirvan Chaudhuri Neha Madan Xiao Huang Jason Park Anjai Lal Executive Summary Our team recommends. A Recombinant Protein for treatment of Multiple
More informationSymptomspesifikke probiotikum. Linda Mulder, MSc. Vårseminaret 2014
Linda Mulder, MSc. Vårseminaret 2014 Content Background on probiotics Intestinal microbiota & health on 3 levels Indication-specific probiotics Strain-specific characteristics Monostrain vs. multispecies
More informationFactors that Lead to the Immunotherapy Gap in Multiple Sclerosis Testing by Karthika Solai
Factors that Lead to the Immunotherapy Gap in Multiple Sclerosis Testing by Karthika Solai Introduction Multiple sclerosis is a disease that affects the central nervous system. Most doctors and scientists
More informationAntibiotic-Associated Diarrhea, Clostridium difficile- Associated Diarrhea and Colitis
Antibiotic-Associated Diarrhea, Clostridium difficile- Associated Diarrhea and Colitis ANTIBIOTIC-ASSOCIATED DIARRHEA Disturbance of the normal colonic microflora Leading to alterations in bacterial degradation
More informationHow To Use An Antibody
GUIDELINES FOR THE PRODUCTION OF ANTIBODIES IN LABORATORY ANIMALS Table of Contents 1. Purpose 2. Choice of Species and Strain 3. Immunizing Antigen 4. Procedures for Polyclonal Antibody Production 5.
More informationPharmacology of the Respiratory Tract: COPD and Steroids
Pharmacology of the Respiratory Tract: COPD and Steroids Dr. Tillie-Louise Hackett Department of Anesthesiology, Pharmacology and Therapeutics University of British Columbia Associate Head, Centre of Heart
More informationUlcerative Colitis & Proctitis. About Ulcerative Colitis & Proctitis
Ulcerative Colitis & Proctitis About Ulcerative Colitis & Proctitis When you first learn that you have ulcerative colitis, you will probably feel overwhelmed. You may not even have heard of ulcerative
More informationTop Down vs. Step Up Therapy Biologics in IBD: Treatment Algorithms. Stephen B. Hanauer, M.D. University of Chicago
Top Down vs. Step Up Therapy Biologics in IBD: Treatment Algorithms Stephen B. Hanauer, M.D. University of Chicago Treatment Goals c.2008 Induce and maintain response/remission Prevent complications Disease
More informationGene Silencing Oligos (GSOs) Third Generation Antisense
Gene Silencing Oligos (GSOs) Third Generation Antisense Walter R. Strapps, Ph.D. Executive Director, RNA Therapeutics Idera Pharmaceuticals Cambridge, MA NASDAQ: IDRA www.iderapharma.com Idera is a leader
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON THE DEVELOPMENT OF NEW MEDICINAL PRODUCTS FOR THE TREATMENT OF ULCERATIVE COLITIS
European Medicines Agency London, 24 January 2008 Doc. Ref. CHMP/EWP/18463/2006 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON THE DEVELOPMENT OF NEW MEDICINAL PRODUCTS FOR THE TREATMENT
More informationCOMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) NOTE FOR GUIDANCE ON THE PRE-CLINICAL EVALUATION OF ANTICANCER MEDICINAL PRODUCTS
The European Agency for the Evaluation of Medicinal Products Human Medicines Evaluation Unit London, 23 July 1998 COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) NOTE FOR GUIDANCE ON THE PRE-CLINICAL
More informationJAK1 and beyond. Investor Presentation January 2014. Copyright 2014 Galapagos NV
JAK1 and beyond Investor Presentation January 2014 Copyright 2014 Galapagos NV Disclaimer This presentation has been prepared by Galapagos and is furnished to you by Galapagos solely for your information.
More informationThe Clinical Trials Process an educated patient s guide
The Clinical Trials Process an educated patient s guide Gwen L. Nichols, MD Site Head, Oncology Roche TCRC, Translational and Clinical Research Center New York DISCLAIMER I am an employee of Hoffmann-
More informationMRC Technology Centre for Therapeutics Discovery
MRC Technology Centre for Therapeutics Discovery fast-tracking discovery and development of novel drugs from academia Dr Duncan Young Business Development Manager UbiFrance Symposium, October 2012 established
More informationUlcerative Colitis. National Digestive Diseases Information Clearinghouse. What is ulcerative colitis (UC)?
Ulcerative Colitis National Digestive Diseases Information Clearinghouse U.S. Department of Health and Human Services NATIONAL INSTITUTES OF HEALTH What is ulcerative colitis (UC)? Ulcerative colitis is
More informationALLIANCE FOR LUPUS RESEARCH AND PFIZER S CENTERS FOR THERAPEUTIC INNOVATION CHALLENGE GRANT PROGRAM PROGRAM GUIDELINES
ALLIANCE FOR LUPUS RESEARCH AND PFIZER S CENTERS FOR THERAPEUTIC INNOVATION CHALLENGE GRANT PROGRAM PROGRAM GUIDELINES DESCRIPTION OF GRANT MECHANISM The Alliance for Lupus Research (ALR) is an independent,
More informationMedical Therapy for IBD
CHILDREN S DIGESTIVE HEALTH & NUTRITION FOUNDATION NORTH AMERICAN SOCIETY FOR PEDIATRIC GASTROENTEROLOGY, HEPATOLOGY AND NUTRITION Medical Therapy for IBD I. INTRODUCTION The treatment of Crohn s disease
More informationDecision systems in quality registries
Decision systems in quality registries Stockholm Dec 9 th, 2014 Jonas Halfvarson, MD, PhD Dept of Gastronterology, Faculty of Medicine and Health, Örebro University 1 Quality registries for chronic diseases
More informationBiologic Treatments for Rheumatoid Arthritis
Biologic Treatments Rheumatoid Arthritis (also known as cytokine inhibitors, TNF inhibitors, IL 1 inhibitor, or Biologic Response Modifiers) Description Biologics are new class of drugs that have been
More informationLawyers / Attorneys: Evaluation of Nationwide Accutane Accidents, Injuries & Death
The Fox Law Firm is Reviewing Potential ACCUTANE Claims. In the United States, jury trials have awarded at least $33 million dollars to patients as compensation for injuries attributed to Accutane use.
More informationTREATING INFLAMMATORY BOWEL DISEASE (IBD) BACKGROUNDER
Press information for journalists only TREATING INFLAMMATORY BOWEL DISEASE (IBD) BACKGROUNDER Why treat IBD? IBD describes a range of chronic diseases of the gastrointestinal system, encompassing Ulcerative
More informationRheumatoid Arthritis. Treating Inflammation. Sequoia Education Systems, Inc http://www.functionalmedicineuniversity.com 1. How is RA Diagnosed?
Rheumatoid Arthritis Causes, Assessment and Treatment How is RA Diagnosed? The following labs make up the basics of ruling in or out RA. Citrullinated Peptide (anti-ccp) Antibodies Rheumatoid factor Erythrocyte
More informationIntroduction to Enteris BioPharma
Introduction to Enteris BioPharma Enteris BioPharma Intelligent Solutions for Oral Drug Delivery Privately held, New Jersey based biotech company Owned solely by Victory Park Capital, a large Chicago based
More informationNon-clinical development of biologics
Aurigon Life Science GmbH Non-clinical development of biologics Requirements, challenges and case studies Committed to Life. Sigrid Messemer vet. med. M4 Seminar March 10 th 2014 Aurigon - your full service
More informationThe Most Common Autoimmune Disease: Rheumatoid Arthritis. Bonita S. Libman, M.D.
The Most Common Autoimmune Disease: Rheumatoid Arthritis Bonita S. Libman, M.D. Disclosures Two googled comics The Normal Immune System Network of cells and proteins that work together Goal: protect against
More informationBasic Overview of Preclinical Toxicology Animal Models
Basic Overview of Preclinical Toxicology Animal Models Charles D. Hebert, Ph.D., D.A.B.T. December 5, 2013 Outline Background In Vitro Toxicology In Vivo Toxicology Animal Models What is Toxicology? Background
More informationINFLAMMATORY BOWEL DISEASE (IBD) MEASURES GROUP OVERVIEW
SPECIFICATION F MEASURES GROUP REPTING ONLY INFLAMMATY BOWEL DISEASE (IBD) MEASURES GROUP OVERVIEW 2012 PHYSICIAN QUALITY REPTING OPTIONS F MEASURES GROUPS: REGISTRY ONLY 2012 PHYSICIAN QUALITY REPTING
More informationLeukapheresis for inflammatory bowel disease
Issue date: June 2005 Leukapheresis for inflammatory bowel disease Understanding NICE guidance information for people considering the procedure, and for the public Information about NICE Interventional
More informationBile Duct Diseases and Problems
Bile Duct Diseases and Problems Introduction A bile duct is a tube that carries bile between the liver and gallbladder and the intestine. Bile is a substance made by the liver that helps with digestion.
More informationYour Life Your Health Cariodmetabolic Risk Syndrome Part VII Inflammation chronic, low-grade By James L. Holly, MD The Examiner January 25, 2007
Your Life Your Health Cariodmetabolic Risk Syndrome Part VII Inflammation chronic, low-grade By James L. Holly, MD The Examiner January 25, 2007 The cardiometabolic risk syndrome is increasingly recognized
More informationApple polyphenols require T cells to ameliorate dextran sulfate sodium-induced colitis and dampen proinflammatory cytokine expression
Article Apple polyphenols require T cells to ameliorate dextran sulfate sodium-induced colitis and dampen proinflammatory cytokine expression Jerod A. Skyberg, Amy Robison, Sarah Golden, MaryClare F. Rollins,
More informationTechnological platforms
Advitech Advitech is a life sciences & technology company Its mission is to discover and commercialize proprietary and evidence-based natural health products Focus on milk, whey and bovine colostrum R&D,
More informationPrior Authorization Guideline
Prior Authorization Guideline Guideline: PS Inj - Alimta Therapeutic Class: Antineoplastic Agents Therapeutic Sub-Class: Antifolates Client: PS Inj Approval Date: 8/2/2004 Revision Date: 12/5/2006 I. BENEFIT
More informationWntResearch. Foxy-5 A unique Phase 1 opportunity to combat the spreading of cancer
WntResearch Foxy-5 A unique Phase 1 opportunity to combat the spreading of cancer Why WntResearch is developing novel anti-cancer drugs Approximately 55 000 Swedish citizens are diagnosed with cancer every
More informationOncos Therapeutics: ONCOS THERAPEUTICS Personalized Cancer Immunotherapy. March 2015. Antti Vuolanto, COO and co-founder
Oncos Therapeutics: Personalized Cancer Immunotherapy ONCOS THERAPEUTICS Personalized Cancer Immunotherapy March 2015 Antti Vuolanto, COO and co-founder 1 History of Oncos Therapeutics 2002 2007 2009 Research
More informationPrior Authorization, Pharmacy and Health Case Management Information. Prior Authorization. Pharmacy Information. Health Case Management
Prior Authorization, Pharmacy and Health Case Management Information The purpose of this information sheet is to provide you with details on how Great-West Life will be assessing and managing your claim
More informationFee-for-service cores for Investigational New Drug enabling studies
UC DAVIS INSTITUTE FOR REGENERATIVE CURES Fee-for-service cores for Investigational New Drug enabling studies Pipeline pathway at UC Davis Institute for Regenerative Cures Basic Research Proof of Concept
More informationFELINE IBD: PATHOPHYSIOLOGY, TREATMENT GOALS, & CLIENT COMMUNICATION
FELINE IBD: PATHOPHYSIOLOGY, TREATMENT GOALS, & CLIENT COMMUNICATION Kara M. Burns, MS, MEd, LVT President, Academy of Veterinary Nutrition Technicians Diarrhea and vomiting is a common complaint from
More informationsubcutaneous initially every 4 weeks then every 12 weeks Coverage Criteria: Express Scripts, Inc. monograph dated 02/24/2010
BENEFIT DESCRIPTION AND LIMITATIONS OF COVERAGE ITEM: PRODUCT LINES: COVERED UNDER: DESCRIPTION: CPT/HCPCS Code: Company Supplying: Setting: Humira (adalimumab subcutaneous injection) Commercial HMO/PPO/CDHP
More informationUPDATED INVESTOR PRESENTATION June 2015
UPDATED INVESTOR PRESENTATION June 2015 Forward-looking Statements All statements in this presentation other than those of historical fact, including statements regarding our clinical development plans
More informationLaparoscopic Surgery of the Colon and Rectum (Large Intestine) A Simple Guide to Help Answer Your Questions
Laparoscopic Surgery of the Colon and Rectum (Large Intestine) A Simple Guide to Help Answer Your Questions What are the Colon and Rectum? The colon and rectum together make up the large intestine. After
More information1) Aug 2005 In Vitro Chromosomal Aberration Study Cytotoxicity (File: TS39) Conclusion No cytotoxicity can be detected at concentrations up to 100%.
Endotoxicity and Cytotoxicity Studies 1) Aug 2005 In Vitro Chromosomal Aberration Study Cytotoxicity (File: TS39) Chinese Hamster Ovary (CHO) cells were grown in monolayer with and without metabolic activation.
More informationID: C13006 Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Ulcerative Colitis NCT00783718 Results Preview Close
Home > Record Summary > Results Section ID: C13006 Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Ulcerative Colitis NCT00783718 Results Preview Close Hide All Participant Flow Participants
More informationC. difficile Infections
C. difficile Infections Introduction C. difficile is a type of bacteria that can cause diarrhea and infection of the colon. This bacterium is more likely to infect patients at hospitals and other healthcare
More informationPersonalised Medicine in MS
Personalised Medicine in MS Supportive Evidence from Therapeutic Trials Ludwig Kappos Neurology and Department of Biomedicine University Hospital CH-4031 Basel LKappos@uhbs.ch Established partially effective
More informationWelcome to the Launch of Biocon s Breakthrough Innovation. For Psoriasis. Treatment
Welcome to the Launch of Biocon s Breakthrough Innovation For Psoriasis Treatment PRESS MEET Bangalore, August 10, 2013 Autoimmune Diseases are on the Rise Globally Autoimmune Disease Segment includes
More informationUlcerative Colitis. National Digestive Diseases Information Clearinghouse
Ulcerative Colitis National Digestive Diseases Information Clearinghouse What is ulcerative colitis? Ulcerative colitis is a chronic, or long lasting, disease that causes inflammation irritation or swelling
More informationIn vivo dose response assays
In vivo dose response assays Tumor assays 1. Tumor growth measurements; tumor growth delay. After irradiation, the tumor is measured daily to determine the mean diameter, or volume. Plot tumor size versus
More informationFocus Biobank Inflammatory Bowel Disease
Focus Biobank Inflammatory Bowel Disease University Hospitals Leuven KU Leuven Isabelle Cleynen, PhD Inflammatory Bowel Disease Crohn s disease (CD) Entire GI tract Transmural Fistulas and/or strictures
More informationEFFECTS OF IRON ON THE IMMUNE SYSTEM
EFFECTS OF IRON ON THE IMMUNE SYSTEM Gert Mayer Department of Internal Medicine IV (Nephrology and Hypertension) Medical University Innsbruck Austria Conflicts of interest Research Support: Amgen, Roche,
More informationSpinning out in the UK personal experiences and perspectives
Professor Neil A. Williams Head of Department of Cellular and Molecular Medicine Founder, Director of Science, KWS BioTest Ltd Founder, Aegis (Hunter-Fleming) Pharmaceuticals Ltd Spinning out in the UK
More informationAnimals (Scientific Procedures) Act 1986. Non-technical summaries granted during 2013. Volume 35
Animals (Scientific Procedures) Act 1986 n-technical summaries granted during 2013 Volume 35 Project Titles and key words Intestinal delivery of agents Oral delivery, diabetes therapy vel Treatments for
More informationNasdaqGS: SNTS. September 5, 2012
NasdaqGS: SNTS September 5, 2012 Safe Harbor This presentation may include forward-looking statements that are based on management s beliefs and assumptions and on information currently available to management.
More informationEffects of Two Proprietary Compounds in Multiple Sclerosis DATE
Effects of Two Proprietary Compounds in a Model of Multiple Sclerosis DATE Authentication This study was conducted under the terms of a Services Agreement between Inc. and CLIENT dated DATE. Sponsor XXX
More informationAAGPs TM Anti-Aging Glyco Peptides. Enhancing Cell, Tissue and Organ Integrity Molecular and biological attributes of lead AAGP molecule
AAGPs TM Anti-Aging Glyco Peptides Enhancing Cell, Tissue and Organ Integrity Molecular and biological attributes of lead AAGP molecule 1 Acknowledgements This presentation was prepared by Dr. Samer Hussein
More informationSaskatchewan Drug Information Services College of Pharmacy and Nutrition, U of S T: (306)966-6340 F:(306)966-2286 www.usask.
Saskatchewan Drug Information Services College of Pharmacy and Nutrition, U of S T: (306)966-6340 F:(306)966-2286 www.usask.ca/druginfo Volume 19, Issue No. 2 March-April, 2002 TO P.O. B 12 OR NOT TO P.O.
More informationESCMID Online Lecture Library. by author
Do statins improve outcomes of patients with sepsis and pneumonia? Jordi Carratalà Department of Infectious Diseases Statins for sepsis & community-acquired pneumonia Sepsis and CAP are major healthcare
More informationResearch Journal of Pharmaceutical, Biological and Chemical Sciences
Research Journal of Pharmaceutical, Biological and Chemical Sciences Protective Effect ofjaft Extract on Acetic Acid Induced UlcerativeColitis in Rats Jafari K 1, Mirzaei A 2 *, and Ghavamizadeh M 1 1
More informationPeptide and Sustained Release Technology to Treat Ocular Diseases and Cancer
Peptide and Sustained Release Technology to Treat Ocular Diseases and Cancer Jordan Green, PhD, Co-Founder and CEO Wendy Perrow, MBA, Senior Business Advisor February 11, 2015 www.asclepix.com Advantages
More informationEvidence of Crohn s Disease. Case Presentation
Witt Wait to Treat tutiled Until Endoscopic Evidence of Crohn s Disease Raymond Cross, MD, MS, AGAF Associate Professor of Medicine Director, IBD Program University of Maryland School of Medicine Co-Director,
More informationNew strategies in anticancer therapy
癌 症 診 療 指 引 簡 介 及 臨 床 應 用 New strategies in anticancer therapy 中 山 醫 學 大 學 附 設 醫 院 腫 瘤 內 科 蔡 明 宏 醫 師 2014/3/29 Anti-Cancer Therapy Surgical Treatment Radiotherapy Chemotherapy Target Therapy Supportive
More informationDiseases of the Colon. Jack Bragg, D.O., F.A.C.O.I.
Diseases of the Colon Jack Bragg, D.O., F.A.C.O.I. Inflammatory Bowel Disease ULCERATIVE COLITIS CROHN S DISEASE Transmural Inflammation Mucosal Ulceration in Colon Ileitis Ileocolitis Colitis Inflammatory
More informationEffectively Exploiting Big Data with Semantics
Effectively Exploiting Big Data with Semantics Thomas C. Rindflesch, Ph.D. National Library of Medicine, National Institutes of Health Digital Government Institute s Government Big Data Conference, October
More information2.1.2 Characterization of antiviral effect of cytokine expression on HBV replication in transduced mouse hepatocytes line
i 1 INTRODUCTION 1.1 Human Hepatitis B virus (HBV) 1 1.1.1 Pathogenesis of Hepatitis B 1 1.1.2 Genome organization of HBV 3 1.1.3 Structure of HBV virion 5 1.1.4 HBV life cycle 5 1.1.5 Experimental models
More informationAutoimmunity and immunemediated. FOCiS. Lecture outline
1 Autoimmunity and immunemediated inflammatory diseases Abul K. Abbas, MD UCSF FOCiS 2 Lecture outline Pathogenesis of autoimmunity: why selftolerance fails Genetics of autoimmune diseases Therapeutic
More informationDrug Therapy Guidelines: Humira (adalimumab)
Drug Therapy Guidelines: Humira (adalimumab) Effective Date: 5/1/08 Committee Review Date: 1/6/01, 9/18/01, 1/15/02, 1/7/03, 1/20/04, 1/18/05, 12/7/05, 10/15/06, 7/2/07, 11/5/07, 3/25/08 Policy Statements:
More informationInternational Symposium on Malignant Mesothelioma 2011 -- curemeso.org
Measles virotherapy for malignant mesothelioma Manish R. Patel, D.O. Assistant Professor of Medicine University of Minnesota June 25, 2011 Medical Treatment of Mesothelioma Majority of patients are not
More informationStem cells and motor neurone disease
Stem cells and motor neurone disease F Stem cell research has fuelled hope of a treatment for a variety of conditions. This information sheet explains what these cells are and includes details of the current
More informationComplications that may occur with ulcerative colitis:
Ulcerative Colitis What is ulcerative colitis? Ulcerative colitis is one of the major forms of inflammatory bowel disease. The other major form is Crohn s disease. Ulcerative colitis is felt to be due
More informationSINPE trial, Ann Surg 2009. Overall morbidity. Minor Major. Infectious Non infectious. Post-hoc analysis WL < %5 (n=379) WL between 5-10% (n=49)
Chinese International Symposium on Nutritional Oncology Changchun, June 20-21 2014 IMMUNONUTRITION IN CANCER PATIENTS IMMUNONUTRITION IN SURGERY OBJECTIVE To get the patient undergoing major surgery for
More informationDiAgRaMs- RAAK PRO. Shirley Kartaram
DiAgRaMs- RAAK PRO Standardization of the bicycle ergometer test as challenge model to assess nutritional effects on intestinal health and the immune system Shirley Kartaram Department Innovative Testing
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Multiple Technology Appraisal
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Multiple Technology Appraisal Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional
More informationTelemedinsk udvikling
F A C UL T Y O F HE AL T H A ND ME D I C A L S C I E N C E S U N I V E R S I T Y O F C O P E N H A G E N Telemedinsk udvikling Motivational Interviewing Sygeplejerskens rolle - i centrum af ehealth Fagligt
More information岑 祥 股 份 有 限 公 司 技 術 專 員 費 軫 尹 20100803
技 術 專 員 費 軫 尹 20100803 Overview of presentation Basic Biology of RNA interference Application of sirna for gene function? How to study mirna? How to deliver sirna and mirna? New prospects on RNAi research
More informationOriginal Policy Date
MP 5.01.20 Tysabri (natalizumab) Medical Policy Section Prescription Drug Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Local Policy/12:2013 Return to Medical Policy Index Disclaimer
More informationCOMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP)
The European Agency for the Evaluation of Medicinal Products Evaluation of Medicines for Human Use London, 17 December 2003 CPMP/EWP/556/95 rev 1/Final COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP)
More information11/10/2014. New Treatments in IBD: When, Whom and How. Background. Background. Options. Disease Assessment. What is the evidence?
New Treatments in IBD: When, Whom and How. Background Options Disease Assessment What is the evidence? Kofi Clarke MD, FACP,FRCP (Lond) Clinical Associate Professor, Chief, Gastroenterology, Hepatology
More informationTransgene Presents Additional Positive Clinical Data from Phase 2b Part of TIME Trial with TG4010 at ESMO
Transgene Presents Additional Positive Clinical Data from Phase 2b Part of TIME Trial with TG4010 at ESMO Statistically significant difference in progression-free survival continues to be seen in non-squamous
More informationPrograma Cooperación Farma-Biotech Neurociencias NT-KO-003
Programa Cooperación Farma-Biotech Neurociencias NT-KO-003 A new oral treatment for Multiple Sclerosis based on a novel mechanism of action Barcelona, 15 de febrero 2011 Programa Cooperación Farma-Biotech
More informationImmune-Mediated Low Platelet or Thrombocyte Count
rally is Customer Name, Street Address, City, State, Zip code Phone number, Alt. phone number, Fax number, e-mail address, web site Immune-Mediated Low Platelet or Thrombocyte Count (Thrombocytopenia)
More informationBuilding innovative drug discovery alliances. Addressing causes not. symptoms in diabetes
Building innovative drug discovery alliances Addressing causes not symptoms in diabetes Evotec AG, Analyst information on CureBeta Alliance with Janssen, Hamburg, 2012 Forward-looking statements Information
More informationSummary and conclusion 2013
The work presented in the thesis is focused on the problems related to the prostate gland. Benign prostatic hyperplasia (BPH) and prostate cancer (PCa) are the two major problems associated with prostate.
More informationFunctional properties of fructans and their potential role in management of intestinal inflammatory pathologies
Functional properties of fructans and their potential role in management of intestinal inflammatory pathologies Dr.ssa Valentina Pasqualetti Unità di Ricerca di Scienze degli Alimenti e della Nutrizione
More informationMEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES `I. Requirements for Prior Authorization of Cytokine and CAM Antagonists
MEDICAL ASSISTANCE HBOOK `I. Requirements for Prior Authorization of Cytokine and CAM Antagonists A. Prescriptions That Require Prior Authorization All prescriptions for Cytokine and CAM Antagonists must
More informationAnimals (Scientific Procedures) Act 1986. Project summaries granted during 2013
Security marking Animals (Scientific Procedures) Act 1986 Project summaries granted during 2013 Volume 43 Project Titles and key words Environmental sensitivity of subclinical disease resistance and resilience
More informationUlcerative Colitis. Living with
Living with Ulcerative Colitis Our Mission: To cure and prevent Crohn s disease and ulcerative colitis through research, and to improve the quality of life of children and adults affected by these digestive
More informationIACUC Guideline RODENT ANESTHESIA & ANALGESIA FORMULARY
Background This guideline is designed to provide a single source of information for investigators that use rodents models of biomedical disease and discovery. The following tables reference contemporary
More information3 months 1.5 months 1.5 months. 1 month
Rabbit monoclonal antibody (Mab) is secreted by the plasma B-cell of the rabbit. Traditional generation of rabbit Mab relies on a rabbit myeloma for B- cell fusion (
More informationIndication: Indication: Protaxos is indicated in adults.
Maklumat tambahan indikasi untuk upload pada laman web Year 2013 Products Approved For Additional Indication (DCA 262 28 Mac 2013) NO PRODUCT (ACTIVE INGREDIENT) 1. 1.1 EVISTA TABLET 60MG [ Raloxifene
More informationMigrene og mikroflora. Linda Mulder, MSc. Vårseminaret 2014
Migrene og mikroflora Linda Mulder, MSc. Vårseminaret 2014 Contents Introduction to migraine Introduction to intestinal barrier The role of the intestine & microbiota in migraine Finding the best probiotic
More informationProposal to Establish the Crohn s and Colitis Center at the University of Miami Miller School of Medicine
Proposal to Establish the Crohn s and Colitis Center at the University of Miami Miller School of Medicine Contents Mission... 1 Background... 2 Services and Programs... 2 Clinical Care... 2 IBD Specialists...
More informationREPORT ASCO 2002 ORLANDO : LUNG CANCER Johan F. Vansteenkiste, MD, PhD, Univ. Hospital and Leuven Lung Cancer Group
REPORT ASCO 2002 ORLANDO : LUNG CANCER Johan F. Vansteenkiste, MD, PhD, Univ. Hospital and Leuven Lung Cancer Group In the 2002 edition of the ASCO meeting, a total of 315 abstracts in the field of respiratory
More informationInflammatory Bowel Disease & Irritable Bowel Syndrome
Volume 10, No. 1 2010 Inflammatory Bowel Disease & Irritable Bowel Syndrome Understanding, Distinguishing and Addressing Edited by Thomas G. Guilliams Ph.D. Inflammatory Bowel Disease...4 Irritable Bowel
More information